細胞ベースアッセイ市場は、2024年の173億ドルから2029年までに243億ドルに成長し、予測期間中に7.1%のCAGRで成長すると予想されます。細胞ベースアッセイ市場の主要なプレーヤーには、BD (米国)、Thermo Fisher Scientific Inc. (米国)、Danaher Corporation (米国)、Merck KGaA (ドイツ)、Agilent Technologies、Inc. (米国)、Lonza(スイス)、Charles River Laboratories (米国)、Bio-Rad Laboratories、Inc. (米国)、Revvity (米国)、Sartorius AG (ドイツ)、Corning Incorporated (米国)、Promega Corporation (米国)、Cell Signaling Technology、Inc. (米国)、Eurofins Scientific (ルクセンブルク)、Enzo Biochem、 Inc. (米国)、Carna Biosciences, Inc. (日本)、Intertek Group plc (英国)、BICO (スウェーデン)、Cell Biolabs, Inc. (米国)、Reaction Biology (米国)、AAT Bioquest, Inc. (米国)、Pestka Biomedical Laboratories, Inc. (米国)、Neuromics (米国)、BPS Bioscience, Inc. (米国)、BellBrook Labs (米国)、Profacgen (米国)、BMG LABTECH (ドイツ)、Hanugen Theraputics(インド)、Altogen Labs (米国)、BioAgilytix (米国)。
目次
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONS COVERED
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 LIMITATIONS
1.7 STAKEHOLDERS
1.8 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MARKET ESTIMATION
2.2.1.1 Insights from Primary Experts
2.2.2 SEGMENTAL ASSESSMENT METHODOLOGY (TOP-DOWN APPROACH)
2.3 MARKET GROWTH FORECAST
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 LIMITATIONS
2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
5.5 SUPPLY CHAIN ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.7.1 ROLE OF RAW MATERIAL VENDORS
5.7.2 ROLE OF PRODUCT PROVIDERS
5.7.3 ROLE OF END USERS
5.7.4 ROLE OF REGULATORY AUTHORITIES
5.8 TECHNOLOGY ANALYSIS
5.8.1 KEY TECHNOLOGIES
5.8.1.1 FLOW CYTOMETRY
5.8.1.2 HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGY
5.8.1.3 HIGH-CONTENT SCREENING (HCS)
5.8.1.4 LABEL-FREE DETECTION
5.8.2 COMPLIMENTARY TECHNOLOGY
5.8.2.1 ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING
5.8.3 ADJACENT TECHNOLOGY
5.8.3.1 NANOTECHNOLOGY
5.9 PATENT ANALYSIS
5.9.1 PATENTS FILLED, BY DOCUMENT TYPE, 2014-24
5.9.2 INNOVATION AND PATENT APPLICATION
5.9.3 TOP APPLICANTS
5.10 KEY CONFERENCES & EVENTS, 2024-2025
5.11 REGULATORY LANDSCAPE
5.11.1 REGULATORY SCENARIO, BY REGION/COUNTRY
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS, BY REGION/COUNTRY
5.12 PORTER’S FIVE FORCES ANALYSIS
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF SUPPLIERS
5.12.4 BARGAINING POWER OF BUYERS
5.12.5 INTENSITY OF COMPETITION RIVALRY
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.13.2 BUYING CRITERIA FOR END USERS
5.14 INVESTMENT AND FUNDING SCENARIO
5.15 TRADE DATA ANALYSIS
5.15.1 IMPORT SCENARIO
5.15.2 EXPORT SCENARIO
5.16 IMPACT OF AI ON CELL BASED ASSAYS MARKET
6 CELL BASED ASSAYS MARKET, BY OFFERING, 2022-2029 (USD Million)
6.1 INTRODUCTION
6.2 CONSUMABLES
6.2.1 REAGENTS
6.2.2 ASSAY KITS
6.2.2.1 REPORTER GENE ASSAYS
6.2.2.2 SECOND MESSENGER ASSAYS
6.2.2.3 CELL GROWTH ASSAYS
6.2.2.4 CELL DEATH ASSAYS
6.2.2.5 OTHER ASSAY KITS
6.2.3 PROBES & LABELS
6.2.4 MICROPLATES
6.2.5 CELL LINES
6.2.5.1 IMMORTALIZED CELL LINES
6.2.5.2 PRIMARY CELL LINES
6.2.5.3 STEM CELL LINES
6.3 INSTRUMENTS
6.4 SOFTWARE
6.5 SERVICES
Note 1: Other assay kits segment includes oxidative stress assay, cell adhesion, and cell migration & invasion, etc.
Note 2: Instruments segment includes flow cytometers, imaging systems, cell analyzers, cell sorters, and microscopes.
Note 3: Software segment includes integrated as well as standalone software.
7 CELL BASED ASSAYS MARKET, BY TECHNOLOGY, 2022-2029 (USD Million)
7.1 INTRODUCTION
7.2 FLOW CYTOMETRY
7.3 HIGH THROUGHPUT SCREENING
7.4 LABEL FREE DETECTION
7.5 OTHER TECHNOLOGIES
Note 4: Other technologies segment includes automated handling and microscopy, etc.
8 CELL BASED ASSAYS MARKET, BY APPLICATION, 2022-2029 (USD Million)
8.1 INTRODUCTION
8.2 DRUG DISCOVERY
8.2.1 TOXICITY STUDIES
8.2.2 PHARMACOKINETIC STUDIES
8.2.3 PHARMACODYNAMIC STUDIES
8.3 BASIC RESEARCH
8.4 GENETIC STUDIES
8.5 OTHER APPLICATIONS
Note 5: Other application segment includes quality control, phytochemical screening, and antibacterial screening, etc.
9 CELL BASED ASSAYS MARKET, BY END USER, 2022-2029 (USD Million)
9.1 INTRODUCTION
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.3 CONTRACT RESEARCH ORGANIZATIONS (CROs)
9.4 ACADEMIC & RESEARCH INSTITUTES
10 CELL BASED ASSAYS MARKET, BY REGION, 2022-2029 (USD Million)
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 UK
10.3.3 FRANCE
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 SOUTH KOREA
10.4.5 AUSTRALIA
10.4.6 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 BRAZIL
10.5.2 MEXICO
10.5.2 REST OF LATIN AMERICA
10.6 MIDDLE EAST
10.6.1 GCC COUNTRIES
10.6.1.1 UNITED ARAB EMIRATES (UAE)
10.6.1.2 SAUDI ARABIA (KSA)
10.6.1.3 REST OF GCC COUNTRIES
10.6.2 REST OF MIDDLE EAST
10.7 AFRICA
Note 6: Rest of Europe includes Switzerland, Russia, Portugal, Poland, Netherlands, Finland, Denmark, Belgium, Austria, Iceland, Ireland, Norway, and Luxembourg
Note 7: Rest of Asia Pacific includes Bangladesh, Bhutan, Nepal, Sri Lanka, Philippines, Singapore, Vietnam, Thailand, Taiwan, Cambodia, and Indonesia
Note 8: Rest of Latin America includes Colombia, Ecuador, Peru, Uruguay, Cuba and Chile
Note 9: Rest of GCC includes Bahrain, Kuwait, Qatar and Oman
Note 10: Rest of Middle East includes Israel, Iran, Iraq, Jordan, Yemen and other countries
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYERS STRATEGY/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CELL BASED ASSAYS MARKET
11.3 REVENUE ANALYSIS
11.4 MARKET SHARE ANALYSIS
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.5.1 COMPANY FOOTPRINT
11.5.5.2 REGION FOOTPRINT
11.5.5.3 OFFERING FOOTPRINT
11.5.5.4 TECHNOLOGY FOOTPRINT
11.5.5.5 APPLICATION FOOTPRINT
11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
11.6.5.1 DETAILED LIST OF KEY STARTUPS/SME PLAYERS
11.6.5.2 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
11.7 VALUATION AND FINANCIAL METRICS
11.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES & APPROVALS
11.9.2 DEALS
11.9.3 OTHER DEVELOPMENTS
12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 THERMO FISHER SCIENTIFIC INC.
12.1.2 SARTORIUS AG
12.1.3 MERCK KGAA
12.1.4 DANAHER CORPORATION
12.1.5 BD (BECTON, DICKINSON AND COMPANY)
12.1.6 PROMEGA CORPORATION
12.1.7 CORNING INCORPORATED
12.1.8 BIO-RAD LABORATORIES, INC.
12.1.9 AGILENT TECHNOLOGIES, INC.
12.1.10 PERKINELMER
12.1.11 LONZA
12.1.12 CELL SIGNALING TECHNOLOGY, INC.
12.1.13 CHARLES RIVER LABORATORIES
12.1.14 EUROFINS SCIENTIFIC
12.1.15 ENZO BIOCHEM INC.
12.1.16 CARNA BIOSCIENCES, INC.
12.1.17 INTERTEK GROUP PLC
12.1.18 BICO
12.2 OTHER PLAYERS
12.2.1 CELL BIOLABS, INC.
12.2.2 BIOAGILYTIX
12.2.3 REACTION BIOLOGY
12.2.4 AAT BIOQUEST, INC.
12.2.5 PESTKA BIOMEDICAL LABORATORIES, INC.
12.2.6 NEUROMICS
12.2.7 BPS BIOSCIENCE, INC.
12.2.8 BELLBROOK LABS
12.2.9 PROFACGEN
12.2.10 BMG LABTECH
12.2.11 HANUGEN THERAPUTICS
12.2.12 ALTOGEN LABS
